John Grabowski
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
John Grabowski has a total of 2 co-authors. Here are the top co-authors by number of shared publications:
Craig. R. Rush
Department of Behavioral Science, University of Kentucky College of Medicine, Lexington, Kentucky, USA
1 shared publicationDavid V. Herin
Department of Psychiatry, University of Minnesota, Minneapolis, Minnesota, USA
1 shared publication
Latest Publications
- 20 October 2020
- Published by Springer Nature
- p. 2188-2193
Substance Abuse: Treatment
- 20 October 2020
- Published by Springer Nature
- p. 624-628
Dependence, Drug
- 1 January 2013
- Published by Springer Nature
- p. 1922-1927
Substance Abuse: Treatment
- 1 January 2013
- Published by Springer Nature
- p. 560-564
Dependence, Drug
Sun‐downing and integration for the advancement of science and therapeutics: the National Institute on Substance Use Disorders (NISUD)
The National Institutes of Health (NIH) is the most prominent funding source for scientific research in the world. It is also a complex and diverse organization, having multiple institutes, centers and offices. NIH emphasizes the need for innovation and collaboration in research to discover critical knowledge, enhance health and prevent disease. Advancement in science requires not only sophisticated methods, but also logical organization. Here, an overview of ‘behavioral research’ (writ large) at NIH is presented, focusing upon the common trinity of ‘alcohol, tobacco/nicotine and other drugs’ and programmatic overlap across entities. Consideration is also given to the origins of institutes and their historical movement across organizational boundaries. Specific issues, concerns and advantages of integration of the National Institute on Drug Abuse and National Institute on Alcoholism and Alcohol Abuse are addressed. It is concluded that advances in understanding, treating and preventing substance use disorders would best be served by (1)review and integration of all related research throughout NIH, (2) logical placement of leadership for this activity in a single institute, here entitled the National Institute on Substance Use Disorders, and (3) close collaboration of this institute with its complementary partner, the National Institute on Mental Health. Thus, NIH can establish an organizational structure and collaborations reflecting the realities of the scientific and disease/health domains. This would make a prominent statement to the world scientific and health communities regarding NIH recognition of the need for innovation (scientific and organizational) and focus upon these myriad interrelated and costly problems.
Sun‐downing and integration for the advancement of science and therapeutics: the National Institute on Substance Use Disorders (NISUD)
The National Institutes of Health (NIH) is the most prominent funding source for scientific research in the world. It is also a complex and diverse organization, having multiple institutes, centers and offices. NIH emphasizes the need for innovation and collaboration in research to discover critical knowledge, enhance health and prevent disease. Advancement in science requires not only sophisticated methods, but also logical organization. Here, an overview of ‘behavioral research’ (writ large) at NIH is presented, focusing upon the common trinity of ‘alcohol, tobacco/nicotine and other drugs’ and programmatic overlap across entities. Consideration is also given to the origins of institutes and their historical movement across organizational boundaries. Specific issues, concerns and advantages of integration of the National Institute on Drug Abuse and National Institute on Alcoholism and Alcohol Abuse are addressed. It is concluded that advances in understanding, treating and preventing substance use disorders would best be served by (1)review and integration of all related research throughout NIH, (2) logical placement of leadership for this activity in a single institute, here entitled the National Institute on Substance Use Disorders, and (3) close collaboration of this institute with its complementary partner, the National Institute on Mental Health. Thus, NIH can establish an organizational structure and collaborations reflecting the realities of the scientific and disease/health domains. This would make a prominent statement to the world scientific and health communities regarding NIH recognition of the need for innovation (scientific and organizational) and focus upon these myriad interrelated and costly problems.
- 18 February 2010
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1187 (1) , 76-100
Agonist‐like pharmacotherapy for stimulant dependence: preclinical, human laboratory, and clinical studies
A variety of natural and synthetic agents have long been used for stimulant properties, with nontherapeutic use producing multiple waves of stimulant abuse and dependence. The multitude of effects of stimulants exist on continua, and accordingly, here we characterize stimulant abuse/dependence and candidate pharmacotherapies in this manner. Behavioral therapy and medications have been investigated for treatment of stimulant abuse/dependence. Effectiveness of some behavioral interventions has been demonstrated. Most medications studied have been found to lack efficacy. However, an expanding literature supports use of agonist‐like medications to treat stimulant abuse/dependence, a strategy effective for nicotine and opiate dependence. The agonist‐like conceptualization for stimulant dependence posits that medications with properties similar to that of the abused drug, but possessing lesser abuse liability, will normalize neurochemistry and stabilize behavior, thus reducing drug use. Data suggest use of a range of medications, froml‐dopa/carbidopa to amphetamine preparations, depending on the severity of use. This report reviews preclinical, human laboratory, and clinical trial data supporting the agonist‐like approach, including risks and benefits. Future directions for development of agonist‐like medications are also discussed.
- 18 February 2010
- Published by Wiley in Annals of the New York Academy of Sciences
- Vol. 1187 (1) , 76-100
Agonist‐like pharmacotherapy for stimulant dependence: preclinical, human laboratory, and clinical studies
A variety of natural and synthetic agents have long been used for stimulant properties, with nontherapeutic use producing multiple waves of stimulant abuse and dependence. The multitude of effects of stimulants exist on continua, and accordingly, here we characterize stimulant abuse/dependence and candidate pharmacotherapies in this manner. Behavioral therapy and medications have been investigated for treatment of stimulant abuse/dependence. Effectiveness of some behavioral interventions has been demonstrated. Most medications studied have been found to lack efficacy. However, an expanding literature supports use of agonist‐like medications to treat stimulant abuse/dependence, a strategy effective for nicotine and opiate dependence. The agonist‐like conceptualization for stimulant dependence posits that medications with properties similar to that of the abused drug, but possessing lesser abuse liability, will normalize neurochemistry and stabilize behavior, thus reducing drug use. Data suggest use of a range of medications, froml‐dopa/carbidopa to amphetamine preparations, depending on the severity of use. This report reviews preclinical, human laboratory, and clinical trial data supporting the agonist‐like approach, including risks and benefits. Future directions for development of agonist‐like medications are also discussed.